Suppr超能文献

口服或静脉注射等剂量泮托拉唑对胃酸分泌的等效抑制作用。

Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole.

作者信息

Hartmann M, Ehrlich A, Fuder H, Lühmann R, Emeklibas S, Timmer W, Wurst W, Lücker P W

机构信息

Byk Gulden Pharmaceuticals, Konstanz, Germany.

出版信息

Aliment Pharmacol Ther. 1998 Oct;12(10):1027-32. doi: 10.1046/j.1365-2036.1998.00406.x.

Abstract

BACKGROUND

Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 system, and linear pharmacokinetics. The recommended oral dose for treatment of acid-related diseases is 40 mg.

METHODS

Using a randomized, crossover study design we compared the ability of 40 mg oral and intravenous pantoprazole to elevate the intragastric pH in healthy volunteers (n = 20, 'per protocol'), during two treatment phases. The duration of each phase was 5 days. Pantoprazole 40 mg was administered once daily either as a tablet or as an intravenous injection. A 24 h pHmetry was used to record the intragastric pH on day 5 of each regimen; this was compared to the baseline curve obtained before each study period. The calculated 90% confidence intervals (90% CI) represent the mean difference in the intragastric pH, attained after intravenous or oral administration. The predefined equivalence range for the 90% CI was +/- 20% for the percentage time at which the gastric pH was at least pH 3 or 4 and +/- 1 unit for the median pH.

RESULTS

Pantoprazole was well tolerated during both treatment phases. The mean of the 24 h median pH was 3.3 and 3.1 for the intravenous and oral treatments, respectively; the corresponding differences were 0.2 (90% CI: - 0.03 to 0.44). For the mean percentage time at which the pH was 3 or above, the respective calculated values were 57% and 51%, with a difference between the two administration routes of only 5.7% (90% CI: 1.8 to 9.6). At an intragastric pH of 4 or above, the mean percentage time was 420% and 38% following intravenous and oral treatment, respectively, with a difference between the treatment routes of only 4.4% (90% CI: 0.6 to 8.3).

CONCLUSIONS

These results imply that the two formulations of pantoprazole can be assumed to be equipotent. Hence, the intravenous formulation of pantoprazole could be considered as an alternative route of administration.

摘要

背景

泮托拉唑是一种质子泵抑制剂,其特点是与细胞色素P450系统相互作用的可能性低,且具有线性药代动力学。治疗酸相关性疾病的推荐口服剂量为40毫克。

方法

采用随机交叉研究设计,我们比较了40毫克口服和静脉注射泮托拉唑在两个治疗阶段提高健康志愿者(按方案分析,n = 20)胃内pH值的能力。每个阶段持续5天。40毫克泮托拉唑每日给药一次,剂型为片剂或静脉注射剂。在每个治疗方案的第5天,采用24小时pH监测记录胃内pH值;并与每个研究期之前获得的基线曲线进行比较。计算得到的90%置信区间(90%CI)代表静脉或口服给药后胃内pH值的平均差异。对于胃内pH值至少为3或4的百分比时间,90%CI的预定义等效范围为±20%;对于中位pH值,等效范围为±1个单位。

结果

在两个治疗阶段,泮托拉唑的耐受性均良好。静脉注射和口服治疗的24小时中位pH值平均值分别为3.3和3.1;相应差异为0.2(90%CI:-0.03至0.44)。对于pH值为3及以上的平均百分比时间,两种给药途径的计算值分别为57%和51%,两者之间的差异仅为5.7%(90%CI:1.8至9.6)。在胃内pH值为4及以上时,静脉注射和口服治疗后的平均百分比时间分别为42%和38%,治疗途径之间的差异仅为4.4%(90%CI:0.6至8.3)。

结论

这些结果表明,泮托拉唑的两种剂型可被认为具有等效性。因此,泮托拉唑的静脉制剂可被视为一种替代给药途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验